Search

Your search keyword '"Queizán JA"' showing total 2 results
Start Over Author "Queizán JA" Journal blood
2 results on '"Queizán JA"'

1. Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Author

Pardal, Emilia, Diez-Baeza, Eva, González-Barca, Eva, Garcia-Cerecedo, Tomas, Monzo, Encarna, Sancho, Juan-Manuel, Moraleda, Jose Maria, Cordoba, Raul, De la Cruz, Fatima, Queizan, JA, Rodriguez-Salazar, Maria, Hernández-Rivas, JA, Navarro, Belen, Diez-Angulo, Rosana, Viguria, Maria Cruz, Vahi, Maria, Peñarrubia, Maria Jesús, Sanchez, Monica, Canales, Miguel, Gonzalez, Tomas, Alonso, Sara, Caballero, Maria Dolores, and Martin, Alejandro

Published
2015
Full Text
View/download PDF

2. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

Author

Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellán P, Bárez A, Peñarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Díaz-Mediavilla J, San Miguel JF, and Gonzalez M

Subjects
Adult, Aged, Antigens, Neoplasm genetics, Cytogenetic Analysis, DNA-Binding Proteins genetics, Disease-Free Survival, Female, Gene Expression, Genetic Markers, Humans, Leukemia, Myeloid, Acute mortality, MDS1 and EVI1 Complex Locus Protein, Male, Middle Aged, Mutation, Nucleophosmin, Prognosis, Proto-Oncogenes genetics, Risk Factors, Spain epidemiology, Survival Rate, Trans-Activators genetics, Transcription Factors genetics, Transcriptional Regulator ERG, Biomarkers, Tumor genetics, Leukemia, Myeloid, Acute genetics, Models, Genetic
Abstract

We have evaluated 9 new molecular markers (ERG, EVI1, MLL-PTD, MN1, PRAME, RHAMM, and WT1 gene-expression levels plus FLT3 and NPM1 mutations) in 121 de novo cytogenetically normal acute myeloblastic leukemias. In the multivariate analysis, high ERG or EVI1 and low PRAME expressions were associated with a shorter relapse-free survival (RFS) and overall survival (OS). A 0 to 3 score was given by assigning a value of 0 to favorable parameters (low ERG, low EVI1, and high PRAME) and 1 to adverse parameters. This model distinguished 4 subsets of patients with different OS (2-year OS of 79%, 65%, 46%, and 27%; P = .001) and RFS (2-year RFS of 92%, 65%, 49%, and 43%; P = .005). Furthermore, this score identified patients with different OS (P = .001) and RFS (P = .013), even within the FLT3/NPM1 intermediate-risk/high-risk subgroups. Here we propose a new molecular score for cytogenetically normal acute myeloblastic leukemias, which could improve patient risk-stratification.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results